Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04118530 · ClinicalTrials.gov registry record
Long Term Arrhythmia Risk and Cardiovascular Events in Hematopoietic Stem Cell Transplant
A clinical trial of Atrial Fibrillation and Atrial Flutter, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 21
- Enrollment target
- 1
- Study location
NCT04118530: Completed study of Atrial Fibrillation and Atrial Flutter, sponsored by Abramson Cancer Center at Penn Medicine.
NCT04118530 is a study of Atrial Fibrillation and Atrial Flutter that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 21 participants, below the 2,997-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04118530, a study of Atrial Fibrillation and Atrial Flutter, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to better understand the following aims: 1. Aim 1: To evaluate the rate of recurrent Atrial Fibrillation (AF)/Atrial Flutter (AFL) in hematopoietic stem call transplant (HCST) patients with incident AF/AFL identified during the initial 30 days of the transplant 2. Aim 2: To evaluate incident episodes of 1) stroke/TIA; 2) other thromboembolic events (not stroke/TIA); 3) Heart failure events; 4) Ischemic heart events 3. Aim 3: To evaluate overall implantation safety in this population
Primary Outcome
Any recurrent episodes of AF/AFL lasting ≥2 minutes identified in ICM monitoring
Conditions Studied
Interventions
- OTHER HSCT Patients
Study Locations (1)
Pennsylvania
- Abramson Cancer Center at University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2021-04-21 |
| Est. Completion | 2024-06-17 |
What the finished NCT04118530 record still lists
NCT04118530 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 2,997-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which HSCT Patients is the first listed.
NCT04118530 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04118530 about?
NCT04118530 is a clinical study titled "Long Term Arrhythmia Risk and Cardiovascular Events in Hematopoietic Stem Cell Transplant". The purpose of this study is to better understand the following aims: 1. Aim 1: To evaluate the rate of recurrent Atrial Fibrillation (AF)/Atrial Flutter (AFL) in hematopoietic stem call transplant (HCST) patients with incident AF/AFL identified during the initial 30 days of the transplant 2. Aim 2...
What is the current status of trial NCT04118530?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2021-04-21. Estimated completion is 2024-06-17.
What conditions does trial NCT04118530 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Atrial Flutter, Hematopoietic Stem Cell Transplant.
What interventions are being tested in trial NCT04118530?
The interventions under investigation include: HSCT Patients (OTHER).
Who is sponsoring clinical trial NCT04118530?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04118530 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04118530's enrollment target sits among peer trials
21 192nd of 202 higher than 10 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI